How does 0N61's PE Ratio compare to its peers?

0N61 is good value based on its Price-To-Earnings Ratio (34.3x) compared to the peer average (35.5x).

How does 0N61's PE Ratio compare vs other companies in the European Healthcare Industry?

0N61 is expensive based on its Price-To-Earnings Ratio (34.3x) compared to the European Healthcare industry average (18.2x).

What is 0N61's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0N61 is good value based on its Price-To-Earnings Ratio (34.3x) compared to the estimated Fair Price-To-Earnings Ratio (35.8x).

What is the Fair Price of 0N61 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

0N61 (€23.62) is trading below our estimate of [[fair value]] (€32.88)

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Amplifon (LSE:0N61) - Stock Price, News & Analysis

0N61 Stock Overview

Engages in the distribution of hearing solutions and the fitting of customized products that help people rediscover various emotions of sound in Europe, the Middle East, Africa, the Americas, and the Asia Pacific. More details

0N61 fundamental analysis
Snowflake Score
Valuation	5/6
Future Growth	3/6
Past Performance	2/6
Financial Health	3/6
Dividends	3/6

Rewards

Trading at 28.2% below our estimate of its fair value

Earnings are forecast to grow 17.55% per year

Analysts in good agreement that stock price will rise by 36.1%

Risk Analysis

Has a high level of debt

Amplifon S.p.A. Competitors

Mediclinic International

LSE:MDC

UK£3.7b

ConvaTec Group

LSE:CTEC

UK£4.9b

Smith & Nephew

LSE:SN.

UK£8.6b

Spire Healthcare Group

LSE:SPI

UK£875.6m

Price History & Performance

Summary of all time highs, changes and price drops for Amplifon
Historical stock prices
Current Share Price	€23.62
52 Week High	€35.12
52 Week Low	€23.38
Beta	0.83
11 Month Change	-15.28%
3 Month Change	-18.01%
1 Year Change	-15.97%
33 Year Change	-46.71%
5 Year Change	-6.12%
Change since IPO	307.83%

Recent updates

Shareholder Returns

	0N61	GB Healthcare	GB Market
7D	-6.4%	-3.9%	-0.3%
1Y	-16.0%	-24.2%	6.1%

Return vs Industry: 0N61 exceeded the UK Healthcare industry which returned -23.8% over the past year.

Return vs Market: 0N61 underperformed the UK Market which returned 5.6% over the past year.

Price Volatility

Is 0N61's price volatile compared to industry and market?
0N61 volatility
0N61 Average Weekly Movement	3.6%
Healthcare Industry Average Movement	6.4%
Market Average Movement	4.7%
10% most volatile stocks in GB Market	10.3%
10% least volatile stocks in GB Market	2.6%

Stable Share Price: 0N61 has not had significant price volatility in the past 3 months compared to the UK market.

Volatility Over Time: 0N61's weekly volatility (4%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1950	12,715	Enrico Vita	corporate.amplifon.com

Amplifon S.p.A. engages in the distribution of hearing solutions and the fitting of customized products that help people rediscover various emotions of sound in Europe, the Middle East, Africa, the Americas, and the Asia Pacific. The company offers Ampli-easy, Ampli-connect, Ampli-energy, and Ampli-mini hearing devices. It also operates Ampli-care, a platform to deliver audiological care experience; and Amplifon App to manage the device functions in real-time directly from smartphone.

Amplifon S.p.A. Fundamentals Summary

How do Amplifon's earnings and revenue compare to its market cap?
0N61 fundamental statistics
Market cap	€5.34b
Earnings (TTM)	€155.88m
Revenue (TTM)	€2.36b

34.3x

P/E Ratio

2.3x

P/S Ratio

Is 0N61 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0N61 income statement (TTM)
Revenue	€2.36b
Cost of Revenue	€1.78b
Gross Profit	€575.22m
Other Expenses	€419.34m
Earnings	€155.88m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

Mar 06, 2025

Earnings per share (EPS)	0.69
Gross Margin	24.38%
Net Profit Margin	6.61%
Debt/Equity Ratio	108.7%

How did 0N61 perform over the long term?

See historical performance and comparison

Dividends

1.2%

Current Dividend Yield

42%

Payout Ratio

0N61 Stock Overview

Rewards

Risk Analysis

Amplifon S.p.A. Competitors

LSE:MDC

UK£3.7b

LSE:CTEC

UK£4.9b

LSE:SN.

UK£8.6b

LSE:SPI

UK£875.6m

Price History & Performance

Recent News & Updates

Amplifon S.p.A. to Report Q4, 2024 Results on Mar 06, 2025

Third quarter 2024 earnings released: EPS: €0.073 (vs €0.099 in 3Q 2023)

Now 21% undervalued after recent price drop

Amplifon S.p.A. to Report Q3, 2025 Results on Oct 29, 2025

Now 20% undervalued after recent price drop

Second quarter 2024 earnings released: EPS: €0.23 (vs €0.23 in 2Q 2023)

Recent updates

Amplifon S.p.A. to Report Q4, 2024 Results on Mar 06, 2025

Third quarter 2024 earnings released: EPS: €0.073 (vs €0.099 in 3Q 2023)

Now 21% undervalued after recent price drop

Amplifon S.p.A. to Report Q3, 2025 Results on Oct 29, 2025

Now 20% undervalued after recent price drop

Second quarter 2024 earnings released: EPS: €0.23 (vs €0.23 in 2Q 2023)

Upcoming dividend of €0.29 per share

First quarter 2024 earnings released: EPS: €0.15 (vs €0.13 in 1Q 2023)

Now 25% overvalued after recent price rise

Now 21% overvalued after recent price rise

Dividend of €0.29 announced

Full year 2023 earnings released: EPS: €0.69 (vs €0.80 in FY 2022)

Now 20% undervalued

Now 21% undervalued

Now 21% undervalued

Third quarter 2023 earnings released

Amplifon S.p.A. to Report Nine Months, 2024 Results on Oct 30, 2024

Second quarter 2023 earnings released: EPS: €0.23 (vs €0.25 in 2Q 2022)

Upcoming dividend of €0.29 per share at 0.8% yield

First quarter 2023 earnings released: EPS: €0.13 (vs €0.14 in 1Q 2022)

Full year 2022 earnings released: EPS: €0.80 (vs €0.73 in FY 2021)

Third quarter 2022 earnings released: EPS: €0.13 (vs €0.10 in 3Q 2021)

Amplifon S.p.A. Provides Earnings Guidance for the Fourth Quarter of 2022

Amplifon S.p.A. to Report Q1, 2023 Results on May 02, 2023

Now 21% undervalued after recent price drop

Now 21% undervalued after recent price drop

Second quarter 2022 earnings released: EPS: €0.25 (vs €0.24 in 2Q 2021)

Investor sentiment deteriorated over the past week

Now 21% undervalued after recent price drop

Upcoming dividend of €0.26 per share

Now 19% undervalued after recent price drop

First quarter 2022 earnings released: EPS: €0.14 (vs €0.10 in 1Q 2021)

Amplifon S.p.A. to Report Q1, 2022 Results on May 03, 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Now 20% undervalued after recent price drop

Third quarter 2021 earnings released: EPS €0.10 (vs €0.13 in 3Q 2020)

Second quarter 2021 earnings released: EPS €0.24 (vs €0.033 in 2Q 2020)

Upcoming dividend of €0.22 per share

First quarter 2021 earnings released: EPS €0.10 (vs €0.023 in 1Q 2020)

Full year 2020 earnings released: EPS €0.45 (vs €0.49 in FY 2019)

Full year 2020 earnings released: EPS €0.45 (vs €0.49 in FY 2019)

Revenue misses expectations

New 90-day low: €31.53

New 90-day high: €36.15

Amplifon S.p.A. (BIT:AMP) signed a definitive agreement to acquire the hearing care business of PJC Investments LLC for $33 million on a debt-free-cash-free basis.

Revenue beats expectations

Third quarter 2020 earnings released: EPS €0.13

New 90-day high: €33.50

Third-quarter earnings released: Revenue beats expectations

Third quarter earnings released

New 90-day high: €30.79

New 90-day high - €29.61

First half earnings released

Amplifon SpA (BIT:AMP) completed the acquisition of Attune Hearing Pty Ltd.

New 90-day high - €27.68

Shareholder Returns

Price Volatility

About the Company

Amplifon S.p.A. Fundamentals Summary